Date
15 November 2022
Report: Pharma firms must boost access for LMICs, R&D for pandemic threats
Mary van Beusekom writes for CIDRAP about the launch of the 2022 Access to Medicine Index. She finds 'encouraging investments' by pharma in increasing access to medicine, though these are tempered by ongoing inequity and very little R&D activity relating to emerging infectious diseases.
Direct links
The article looks at the 'snapshot' the Access to Medicine Index provides on pharmaceutical company performance. All 20 companies in scope have, for the first time, an access-to-medicine strategy, with six of them having developed access plans for all their late-stage projects.
Digging deeper, the article covers the fact that only 15% of these access plans include one of the 27 low-income countries in scope, with upper-middle income countries far more likely to be considered.
Read the article on the CIDRAP website.